(Total Views: 111)
Posted On: 04/26/2019 2:10:42 PM
Post# of 74551
$HZNP News Article - New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED) https://marketwirenews.com/news-releases/new-...66942.html
(0)
(0)
My Twitter: WhyteStocks
